14 October 2016
EMA/679224/2016
Inspections, Human Medicines Pharmacovigilance & Committees Division
Committees and Inspections Department

Scientific recommendation on classification of advanced therapy medicinal products

Article 17 – Regulation (EC) No 1394/2007

Disclaimer: This document is a summary for public release of a scientific recommendation on classification of advanced therapy medicinal products. The original text adopted by the Committee for Advanced Therapies (CAT) has been redacted to delete commercially confidential information.

The present scientific recommendation refers exclusively to the case as presented to the European Medicines Agency (EMA) without prejudice to future evaluations by the Agency.

It is stressed that the scientific recommendation on advanced therapy classification does not amount to any endorsement of the plausibility of the product, including the mode of action or therapeutic indication(s) claimed by the applicant.

Brief description (or name when available) of the active substance(s)

Recombinant adeno-associated viral vector serotype 8 (AAV8) encoding human glucose-6-phosphatase-α (G6Pase or G6PC).

Brief description of the finished product

Concentrate for solution for infusion.

Proposed indication

Glycogen storage disease type Ia (von Gierke disease).

EMA/CAT conclusion

On the basis that the product:

- The product contains a biological medicinal product as the active substance;

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Send a question via our website www.ema.europa.eu/contact

- The active substance is a recombinant nucleic acid administered to human beings with a view to adding a genetic sequence;
- Its therapeutic effect relates directly to the product of the genetic expression of this sequence

the EMA/CAT considers that the Product falls within the definition of a gene therapy medicinal product.